Cyclo Therapeutics: Clinical-Stage Biotech Targeting Alzheimer’s and Other Unmet Medical Needs

Facebooktwitterlinkedinmail

Cyclo Therapeutics: Clinical-Stage Biotech Targeting Alzheimer’s and Other Unmet Medical Needs

Cyclo Therapeutics: (OTCQB: CTDH) is a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease. The Company’s Trappsol® Cyclo™, an orphan drug designated product in the United States and Europe, is used to treat Niemann-Pick Disease Type C (NPC), a rare and fatal genetic disease, on a compassionate use basis as well as in three ongoing formal clinical trials. The Company’s Scientific Advisory Board endorsed Alzheimer’s Disease (AD) as the company’s next drug development indication. The Company was authorized by the FDA to use Trappsol® Cyclo™ for a late-onset AD patient under a Compassionate Use Program which began intravenous dosing in May 2018.

Facebooktwitterlinkedinmail